Compare Crispr Therapeutics AG (CRSP) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs PubMatic Inc — how do they compare? Crispr Therapeutics AG trades at $53.79 (market cap $5.23B), while PubMatic Inc trades at $17.21 (market cap $804.41M). The key difference: Crispr Therapeutics AG is far larger — about 6.5× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | PUBM | |
|---|---|---|
Market Cap | $5.23B | $804.41M |
Sector | Health | Technology |
52-Week High | $76.78 | $17.78 |
52-Week Low | $44.34 | $6.28 |
Enterprise Value | $3.65B | $707.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
PubMatic (PUBM) trades at $17.76, down slightly by 0.11% today. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Recent Q2 2026 earnings beat expectations with 10.5% revenue growth and a significant EPS surprise. The company is focusing on high-margin segments like mobile app and CTV advertising, supported by new AI product launches and executive appointments.
The outlook is cautiously optimistic with a consensus price target of $20.83, implying 17% upside. However, risks include persistent net losses, a high P/E ratio of 132, and competitive pressures in digital advertising. Analyst sentiment is split evenly between Buy and Hold ratings, reflecting uncertainty around near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
